Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Bristol Myers Squibb : U.S. Patents Awarded to Inventors in Connecticut (Nov. 10)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:38pm CEST

ALEXANDRIA, Va., Nov. 10 -- The following federal patents were awarded to inventors in Connecticut.

***

Temptime Assigned Patent for Computing Systems

ALEXANDRIA, Va., Nov. 10 -- Temptime, Morris Plains, New Jersey, has been assigned a patent (9,811,632) developed by six co-inventors for "computing systems and methods for electronically indicating the acceptability of a product." The co-inventors are Frederick Robert Grabiner, Livingston, New Jersey, Carl Michael Lentz, Cedar Knolls, New Jersey, Emily Moore, Haddam, Connecticut, Thaddeus Prusik, Stroudsburg, Pennsylvania, Nicholas Puro, Briarcliff Manor, New York, and Bruce-Erik Osborn, West Vancouver, Canada. The abstract states: "In part, the invention relates to computing systems and methods for electronically indicating the acceptability of a product. An image capture and communication device may analyze a product label that includes one or more monitors, authentication elements, and identification elements. The image capture and communication device may determine the type and features of the monitors, authentication elements, and identification elements. The image capture and communication device may transmit data based on the type and features to a host server, which may transmit data associated with the host product to the image capture and communication device in, inter alia, the form of an acceptability report."

The patent application was filed on Dec. 28, 2015 (14/981,457). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,811,632.PN.&OS=PN/9,811,632&RS=PN/9,811,632

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Immunomodulators

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,625) developed by two co-inventors for immunomodulators. The co-inventors are Kenneth M. Boy, Durham, Connecticut, and Paul Michael Scola, Glastonbury, Connecticut. The abstract states: "The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases."

The patent application was filed on March 14, 2016 (15/068,993). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,625.PN.&OS=PN/9,809,625&RS=PN/9,809,625

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,573) developed by six co-inventors for "substituted pyridine derivatives useful as GSK-3 inhibitors." The co-inventors are Guanglin Luo, Madison, Connecticut, Ling Chen, Middletown, Connecticut, Gene M. Dubowchik, Middlefield, Connecticut, Swanee E. Jacutin-Porte, Madison, Connecticut, Prasanna Sivaprakasam, Middletown, Connecticut, and John E. Macor, Washington Crossing, Pennsylvania. The abstract states: "The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system."

The patent application was filed on Nov. 3, 2014 (15/033,770). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,573.PN.&OS=PN/9,809,573&RS=PN/9,809,573

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

P.F. Laboratories, Purdue Pharma, Purdue Pharmaceuticals Assigned Patent for Pharmaceutical Formulation Containing Opioid Agonist

ALEXANDRIA, Va., Nov. 10 -- P.F. Laboratories, Totowa, New Jersey, Purdue Pharma, Stamford, Connecticut, and Purdue Pharmaceuticals, Wilson, North Carolina, have been assigned a patent (9,808,453) developed by three co-inventors for "pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent." The co-inventors are Benjamin Oshlack, Boca Raton, Florida, Curtis Wright, Rockport, Massachusetts, and Christopher Breder, Greenwich, Connecticut. The abstract states: "Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid."

The patent application was filed on Dec. 19, 2016 (15/384,229). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,453.PN.&OS=PN/9,808,453&RS=PN/9,808,453

Written by Amal Ahmed; edited by Sudarshan Harpal.

TARGETED NEWS SERVICE: Myron Struck, editor; 703/304-1897; editor@targetednews.com; http://www.targetednews.com

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
09/20BRISTOL MYERS SQUIBB : Investigators from Bristol-Myers Squibb Release New Data ..
AQ
09/20BRISTOL MYERS SQUIBB : Novel, Oral, Selective TYK2 Inhibitor Delivered Significa..
AQ
09/20REPORTS FROM BRISTOL-MYERS SQUIBB AD : a...
AQ
09/20BRISTOL MYERS SQUIBB : CTLA4 targeted therapy plus PD-1 targeted therapy could b..
AQ
09/18BRISTOL MYERS SQUIBB : Statement on Resignation of Dr. Jose Baselga
AQ
09/18BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol-Myers Squibb&..
BU
09/15NATERA : Signs Agreement with Bristol-Myers Squibb to Investigate Signatera ctDN..
AQ
09/14BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers (form 8-K)
AQ
09/14BRISTOL MYERS SQUIBB : Statement on Resignation of Dr. José Baselga
PU
09/14BRISTOL MYERS SQUIBB : Announces Dividend
AQ
More news
News from SeekingAlpha
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/24Gilead to launch generic versions of Epclusa and Harvoni 
09/23Big Pharma Levers Up As Deal Activity Settles Down 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
Financials ($)
Sales 2018 22 280 M
EBIT 2018 5 828 M
Net income 2018 4 663 M
Finance 2018 188 M
Yield 2018 2,63%
P/E ratio 2018 20,98
P/E ratio 2019 17,00
EV / Sales 2018 4,50x
EV / Sales 2019 4,19x
Capitalization 101 B
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 59,8 $
Spread / Average Target -2,9%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY1.58%100 507
JOHNSON & JOHNSON2.26%383 312
PFIZER21.29%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092